Olema Pharmaceuticals, Inc.
OLMA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.94 | 0.36 | -0.02 | -0.02 |
| FCF Yield | -30.52% | -13.19% | -84.12% | -14.13% |
| EV / EBITDA | -1.44 | -5.44 | -0.72 | -1.21 |
| Quality | ||||
| ROIC | -34.66% | -40.95% | -53.46% | -24.76% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.81 | 0.87 | 0.78 | 0.71 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -24.82% | -1.58% | -57.71% | -162.35% |
| Safety | ||||
| Net Debt / EBITDA | 0.97 | 0.63 | 0.20 | 3.98 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |